As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
7 Analysts have issued a Phio Pharmaceuticals Corp. forecast:
7 Analysts have issued a Phio Pharmaceuticals Corp. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -7.04 -7.04 |
25%
25%
|
EBIT (Operating Income) EBIT | -7.05 -7.05 |
25%
25%
|
Net Profit | -6.77 -6.77 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Head office | United States |
CEO | Robert Bitterman |
Employees | 5 |
Founded | 2011 |
Website | phiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.